Piomic
Piomic Medical AG develops and commercializes the COMS One Therapy System, a non-invasive medical device that combines red/near-infrared light with pulsed magnetic fields to treat chronic, hard-to-heal wounds in hospitals and wound care clinics across Europe, with US entry pending FDA De Novo clearance.
- Company typePrivate
- Founded2016
- HeadquartersZürich, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Piomic does
Piomic Medical AG is a Zurich-based medical device company founded in 2016 that has developed the COMS One Therapy System, a non-invasive platform for treating hard-to-heal chronic wounds. The underlying COMS (Concurrent Optical and Magnetic Stimulation) technology combines red and near-infrared LED light (660 nm and 830 nm) with extremely low frequency pulsed magnetic fields to reactivate mitochondrial function, nitric oxide production, and ATP generation, accelerating wound closure in indications such as therapy-refractory diabetic foot ulcers, venous leg ulcers, arterial ulcers, and pressure ulcers. The commercial product comprises the reusable COMS One therapy unit together with single-use consumables — the patent-protected COMStouch sterile wound adapter and the COMSfix/COMSrefix fixation bands — sold through a quote-based, direct B2B channel to wound care clinics, hospitals, vascular surgery and podiatry practices in Europe.
The business model is a capital equipment plus recurring consumables model. Piomic has CE-MDR certification for the European market, where it soft-launched in 2021 and has since treated more than 2,000 patients. In the United States the device is investigational; Piomic is running the MAVERICKS pivotal IDE trial across up to 30 centers and 224 patients for diabetic foot ulcers, has secured Medicare Category B coverage and FDA Breakthrough Device Designation, and holds newly created AMA Category III CPT codes effective January 2025 to support post-approval reimbursement. The company is also developing COMS Blue, a next-generation system funded by Eurostars and built with Fraunhofer IZM and reanmo, which adds real-time diagnostics and digital health applications targeting antibiotic-independent wound infection treatment. Total disclosed funding is CHF 7.5 million in Series A (August 2022) led by Swiss Diabetes Venture Fund, with additional non-dilutive support from the European Innovation Council and Eurostars.
Piomic is venture-backed, privately held, and operates a US subsidiary (Piomic Medical U.S.) under President Bernard Laurel, while European operations are led by co-founder and CEO Christopher Hertz alongside COO Martin Walti, CTO Jari Kruth, and CSO Dr. Jürg Fröhlich. The board and advisory lineup — including former Mölnlycke Healthcare and Smith+Nephew Advanced Wound Care leaders — reflects a deliberate positioning toward US commercialization of a clinically validated, reimbursement-ready, first-in-class combination therapy.
Piomic firmographics
Firmographics- Name
- Piomic
- Legal name
- Piomic Medical AG
- Website
- https://piomic.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Piomic Medical AG develops and commercializes the COMS One Therapy System, a non-invasive medical device that combines red/near-infrared light with pulsed magnetic fields to treat chronic, hard-to-heal wounds in hospitals and wound care clinics across Europe, with US entry pending FDA De Novo clearance.
- Ownership category
- akta.pro rank
Piomic industry classification
Industry- Product category
- Advanced Wound Care Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Wound Care & Ulcer Management (HLAKACAN)
Keywords
Where Piomic is headquartered
LocationHeadquarters
- HQ city
- Zürich
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Piomic business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- COMS One Device Sales: The reusable COMS One therapy unit is sold to healthcare institutions and clinics. The device enables cleaning and disinfection between applications with different patients, providing a durable capital equipment revenue stream.
- Consumables (COMStouch, COMSfix): Single-use sterile accessories (COMStouch wound adapter, COMSfix fixation band) required for each treatment session create recurring consumables revenue. COMSrefix is a reusable multi-patient-use option.
- Clinical Trial Services: Revenue from clinical trial operations including Medicare Category B coverage for MAVERICKS study in the US, supporting reimbursement pathway development and future commercialization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | B2B Enterprise Pricing - Direct Sales |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Piomic product offering
Product offeringCore offering
Piomic develops, manufactures, and commercializes the COMS® One Therapy System, a CE-MDR certified medical device for treating hard-to-heal chronic wounds. The system combines a reusable therapy unit that emits red/near-infrared light (660nm and 830nm) and extremely-low-frequency pulsed magnetic fields, with single-use sterile consumables (COMStouch wound adapter, COMSfix/COMSrefix fixation bands). Treatment is delivered in approximately 16-minute sessions, typically twice weekly over a two-month duration, and is sold to hospitals, wound care clinics, vascular surgery and podiatry practices across Europe.
Product overview
Piomic offers the COMS® One Therapy System, a unified medical device platform for treating hard-to-heal wounds through Concurrent Optical and Magnetic Stimulation (COMS). The system comprises three components: the COMS® One reusable therapy unit, the COMStouch sterile wound adapter (single-use), and COMSfix/COMSrefix fixation bands. The core technology combines red/near-infrared light (660nm and 830nm wavelengths) with extremely low-frequency pulsed magnetic fields to improve mitochondrial function, nitric oxide production, and ATP generation, reactivating the body's natural wound healing cascade. The company is also developing COMS® Blue, which will add real-time diagnostics and digital health capabilities for antibiotic-independent infection treatment.
Differentiator
Problem solved
Functional benefit
Brands
- COMS Blue: Development project for antibiotic-independent wound infection treatment with real-time diagnostics and digital health applications, awarded Eurostars funding in March 2025
Products and services
- COMS® One Therapy System Medical device system for treating hard-to-heal chronic wounds using Concurrent Optical and Magnetic Stimulation (COMS). Delivers combined 660nm red and 830nm near-infrared optical stimulation with extremely low-frequency pulsed magnetic fields to reactivate and accelerate the body's natural wound healing cascade via improved mitochondrial function, nitric oxide production, and ATP generation. Sold to hospitals, wound care clinics, vascular surgery, and podiatry practices.
- COMStouch Sterile Wound Adapter Patent-protected sterile single-use wound adapter enabling hands-free mounting on the COMS One therapy device with soft body adaptation. Disposable after each treatment session. Sold to healthcare institutions as a recurring consumable for the COMS One Therapy System.
- COMSfix Flexible Fixation Band Single-use flexible fixation band with hook-and-loop closure and self-adhesive properties for securing the COMS One therapy device during treatment. Sold to healthcare institutions as a recurring consumable accessory.
- COMSrefix Flexible Fixation Band Reusable single-patient-use flexible fixation band with hook-and-loop closure, hand-cleanable between applications. Provides an alternative multi-use fixation option for the COMS One therapy device. Sold to healthcare institutions.
Quantifiable outcome
- 69% mean wound surface reduction with 50% complete wound closures in 12 weeks
- +3 more outcomes
Companies that use Piomic
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Piomic technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Piomic partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Fraunhofer IZMcoreCollaboration partner in Eurostars-funded COMS Blue project. Fraunhofer IZM provides engineering expertise in reliability and microintegration for development of next-generation COMS Blue therapy system with real-time diagnostics for antibiotic-independent wound infection treatment.
- reanmocoreSoftware collaboration partner in Eurostars COMS Blue project. reanmo contributes user-centric digital solutions and software capabilities for digital health applications integrated with COMS Blue wound infection treatment platform.
- Aksone Nouvong, DPM (UCLA)coreNational Principal Investigator for MAVERICKS FDA IDE clinical trial. Dr. Nouvong from David Geffen School of Medicine at UCLA leads pivotal study design and execution for COMS therapy in diabetic foot ulcers across 30 US sites.
- Prof. Sebastian Probst (EWMA)coreSponsor and Principal Investigator of NAZARÉ post-market clinical study. Prof. Sebastian Probst, Past-President of European Wound Management Association (EWMA), leads consortium of European KOLs evaluating COMS therapy in chronic vascular leg ulcers.
- Andy Weymann (Advisor)minorAdvisor with over 25 years MedTech leadership experience including CMO at Smith+Nephew where he led Advanced Wound Care division. Provides strategic guidance and industry network connections.
- University of Zurich/ETH ZurichminorFounders Christopher Hertz (ETH M.Sc. Molecular Health Science), Jari Kruth (ETH M.Sc. Mechanical Engineering), and Dr. Jürg Fröhlich (ETH Dr. sc. techn.) have connections to ETH Zurich. ETH research group 'Electromagnetics in Biology and Medicine' contributed to technology development.
- sitem-inselminorSwiss medical technology incubator. Piomic was selected for inaugural cohort of sitem-insel Innovation Voucher program providing in-kind expert support to advance medical device solutions.
Scale indicators7 records
Recent moves10 records
Expansion highlights7 records
Piomic competitors and assessment
Company assessmentDirect peers
- Mölnlycke Health Care: Mölnlycke is a global leader in advanced wound care (Mepilex, Avance, etc.) and previously had an electrical stimulation wound therapy business led by Piomic's chairman. Piomic targets the same hospital wound care buyers and competes for the same diabetic foot ulcer and pressure ulcer treatment slots.
- ConvaTec: ConvaTec is a focused advanced wound care and ostomy company with products such as AQUACEL and InnovaMatrix. It sells into the same wound care clinics and hospitals that Piomic targets with COMS One, making it a direct competitor for refractory ulcer treatment slots.
- Coloplast: Coloplast's Wound & Skin Care business sells Biatain, Triadema, and other advanced wound dressings directly to wound care clinicians across Europe and the US. It targets the same chronic wound patient population and competes for hospital formulary positions.
- Organogenesis: Organogenesis sells Apligraf, Dermagraft, and other living cell-based wound care products for diabetic foot ulcers and venous leg ulcers. It is the most direct biologic competitor to COMS One for refractory diabetic foot ulcers, the primary MAVERICKS indication.
Broad incumbents
- Smith+Nephew: Smith+Nephew's Advanced Wound Care division offers PICO NPWT, ACTICOAT, and other wound care products and was historically led by Piomic's advisor. It competes across the same advanced wound care indications Piomic is targeting, but as part of a much broader sports medicine and orthopedics portfolio.
- 3M Health Care (Solventum): Following the spin-off of Solventum, 3M's/KCI's wound care franchise (including V.A.C. negative pressure wound therapy) remains one of the largest in advanced wound care. It competes with Piomic for refractory wound cases in hospitals and ambulatory surgery centers.
- Integra LifeSciences: Integra offers a portfolio of regenerative wound care technologies (Integra Dermal Regeneration Template, PriMatrix, AmnioExcel) sold to hospitals and wound care clinics. It competes in the advanced chronic wound space and represents a potential acquirer or partner for Piomic.
- Cardinal Health: Cardinal Health distributes advanced wound care products from multiple manufacturers to hospitals, home health agencies, and wound care clinics across the US. While not a direct product competitor, it is a key channel partner that Piomic must access to scale US commercial sales.
Emerging players
- MiMedx: MiMedx sells dehydrated amniotic membrane allografts (EpiFix, AmnioFix) for chronic wound healing, including diabetic foot ulcers. It targets a similar patient population with a different mechanism, competing for the same advanced wound care reimbursement dollars.
- Bioventus: Bioventus offers active wound healing products including ultrasonic and electrical stimulation modalities (e.g., SonicOne, LIPUS). Its energy-based wound care portfolio overlaps directly with Piomic's COMS mechanism and represents the closest technology analog.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Piomic social profiles
Digital presencePiomic compliance and trust
Trust signalCompliance2 records
Piomic financial estimates
Financial estimateRevenue estimate
Valuation estimate
Piomic leadership team
Management profileNumber of profiles
Profiles14 records
Piomic subsidiaries and ownership
Company hierarchySubsidiaries1 record
Piomic funding detail
Funding detailFunding overview
Funding rounds4 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Piomic M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Piomic
What does Piomic do?
Piomic develops, manufactures, and commercializes the COMS® One Therapy System, a CE-MDR certified medical device for treating hard-to-heal chronic wounds. The system combines a reusable therapy unit that emits red/near-infrared light (660nm and 830nm) and extremely-low-frequency pulsed magnetic fields, with single-use sterile consumables (COMStouch wound adapter, COMSfix/COMSrefix fixation bands). Treatment is delivered in approximately 16-minute sessions, typically twice weekly over a two-month duration, and is sold to hospitals, wound care clinics, vascular surgery and podiatry practices across Europe.
Is Piomic a public or private company?
Piomic is a private company. It is classified as venture growth investor backed and is currently operating.
When was Piomic founded?
Piomic was founded in 2016. It employs 11 to 50 people.
Where is Piomic based?
Piomic is headquartered in Zürich, Switzerland, in the Europe region.
How does Piomic make money?
Three revenue lines are on record. COMS One Device Sales are the primary driver. The others are consumables (COMStouch, COMSfix) and clinical Trial Services.
Who are Piomic's main competitors?
Direct peers on record are Mölnlycke Health Care, ConvaTec, Coloplast and Organogenesis. Broad incumbents are Smith+Nephew, 3M Health Care (Solventum), Integra LifeSciences and Cardinal Health. Emerging players are MiMedx and Bioventus.
Does Piomic have an API?
No public API is recorded for Piomic.
What industry is Piomic in?
Piomic's product category is Advanced Wound Care Medical Devices. Its primary akta.pro industry code is HLAKACAN, Wound Care & Ulcer Management. Its NAICS code is 334510 and its SIC code is 3845.